Datametrex Provides Update to Normal Course Issuer Bid

Toronto, Ontario--(Newsfile Corp. - July 5, 2022) - Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTCQB: DTMXF) (the "Company" or "Datametrex") announces that it purchased an aggregate of 7,122,500 common shares of the Company ("Common Shares") at an average purchase price of $0.1298 during the month of June 2022, pursuant to the Company's previously announced normal course issuer bid ("NCIB"). The Company intends to continue purchasing its Common Shares under its NCIB and will be updating the market on the progress on a monthly basis.

Datametrex's current NCIB commenced on June 8, 2022 and expires on June 8, 2023, pursuant to which a maximum of 17,808,301 Common Shares may be purchased, representing approximately 5% of the issued and outstanding Common Shares as at the time of the commencement of the NCIB. To date, Datametrex has purchased and cancelled an aggregate of 7,122,500 common shares.

All Common Shares purchased under the NCIB are being purchased on the open market by PI Financial through the facilities of the TSX-V as well as through other designated exchanges and alternative trading systems in Canada in accordance with applicable regulatory requirements. All Common Shares purchased will be at the prevailing market price at the time of purchase and will be subsequently cancelled.

"The Company is thrilled to have the NCIB program in place to increase return to our shareholders. Creating long lasting shareholder value is priority and we look forward to growing the Company while making an impactful difference with our investors," said Marshall Gunter, CEO of the Company.

About Datametrex

Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning. Datametrex' mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain. For additional information on Datametrex and other corporate information, please visit the Company's website at www.datametrex.com.

For further information:

Investor Relations & Communications

Priya Monique Atwal, Director
Email: [email protected]
Tel: 416-901-5611 x 204

Marshall Gunter, CEO
Email: [email protected]
Tel: 514-295-2300

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements, including statements regarding the Bid. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control. Except as required by law, the Company does not undertake to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

###

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/130027